Production (Stage)
ABVC BioPharma, Inc.
ABVC
$1.15
-$0.06-4.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 13.60K | 380.00K | 117.10K | 1.20K |
| Total Other Revenue | -- | -11.60K | 9.30K | -- | -- |
| Total Revenue | -- | 2.00K | 389.30K | 117.10K | 1.20K |
| Cost of Revenue | -- | 0.00 | 300.00 | 200.00 | 300.00 |
| Gross Profit | -- | 2.00K | 389.00K | 117.00K | 900.00 |
| SG&A Expenses | 664.10K | 304.10K | 301.20K | 1.05M | 2.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 45.50K | -16.90K | -- | -- |
| Total Operating Expenses | 693.00K | 381.70K | 322.50K | 1.09M | 2.84M |
| Operating Income | -693.00K | -379.70K | 66.80K | -976.60K | -2.84M |
| Income Before Tax | -944.20K | 128.90K | -133.90K | -1.38M | -2.93M |
| Income Tax Expenses | -- | 0.00 | 400.00 | -110.90K | -- |
| Earnings from Continuing Operations | -944.20K | 128.90K | -134.30K | -1.27M | -2.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 102.10K | 100.40K | -52.30K | 260.00K | 93.50K |
| Net Income | -842.10K | 229.30K | -186.60K | -1.01M | -2.83M |
| EBIT | -693.00K | -379.70K | 66.80K | -976.60K | -2.84M |
| EBITDA | -686.00K | -369.30K | 73.80K | -963.30K | -2.84M |
| EPS Basic | -0.06 | 0.02 | -0.02 | -0.09 | -0.29 |
| Normalized Basic EPS | -0.03 | 0.02 | -0.01 | -0.05 | -0.18 |
| EPS Diluted | -0.06 | 0.02 | -0.02 | -0.09 | -0.29 |
| Normalized Diluted EPS | -0.03 | 0.02 | -0.01 | -0.05 | -0.18 |
| Average Basic Shares Outstanding | 14.97M | 13.20M | 12.41M | 11.32M | 9.74M |
| Average Diluted Shares Outstanding | 14.97M | 13.20M | 12.41M | 11.32M | 9.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |